Aim: To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications. Methods: Subjects completed a survey recalling medication effectiveness and side effects and then underwent pharmacogenetic testing. Results: Our 15 gene pharmacogenetic panel predicted efficacy (p < 0.001) but did not predict side effect tolerability (p = 0.70) in a group of 352 patients. The pharmacogenetic panel and reported efficacy corresponded 60% of the time and medication tolerability agreed 71% of the time. Conclusion: Pharmacogenetic testing may be a useful adjunct to predict efficacy of medications used to treat depression.
CITATION STYLE
Tonozzi, T. R., Braunstein, G. D., Kammesheidt, A., Curran, C., Golshan, S., & Kelsoe, J. (2018). Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: A retrospective, cross-sectional study. Pharmacogenomics, 19(15), 1169–1179. https://doi.org/10.2217/pgs-2018-0088
Mendeley helps you to discover research relevant for your work.